In cancer context, protects cells from induced-DNA damage and apoptosis. Acts, at least in part, through PI3K/AKT/NFKB signaling pathway and by preventing POLB degradation. Decreases POLB ubiquitation and stabilizes its protein levels. Interacts with POLB (PubMed:25260657). Interacts with AKT1 and MT1X (PubMed:23251525). May interact with FAM168B (PubMed:22771904). Associated with cisplatin (DDP)-resistance and radioresistance in the treatment of lung cancer as well as oral squamous cell carcinoma and poor clinical outcome in patients. Belongs to the FAM168 family. Extended N-terminus.